AFMD News and Press, Affimed N.V. From 11/07/23

MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, Novem...

Addition of Affimed’s innate cell engager (ICE ® ) improves cytotoxicity of natural killer (NK) cells and CAR-NK cells NK cells with ICE ® show at least comparable anti-tumor cell efficacy to CAR-NK cells with ICE ® ICE ® combined with NK cells o...

In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a 72.2% complete response rate as of the July 2023 cut-off date for data included in the abstract ...

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’...

2023-10-04 06:59:08 ET Affimed N.V. ( NASDAQ: AFMD ) to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 4, 2023. This announcement has no immediate effect on the listing or trading of the Company’s common ...

MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received approva...

MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with a com...

MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Financial Of...

2023-09-12 07:20:47 ET More on Affimed Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial information for Affimed Affimed N.V. ( AFMD ) Q2 2023 Earnings Call Transcript For further details see: Affime...

AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed/refractory Hodgkin lymphoma The FDA’s fast track de...